While single-agent belantamab mafodotin may induce ocular events among patients with relapsed or refractory multiple myeloma (RRMM), many patients will recover from these effects without discontinuing treatment, according to research presented at the British Society of Haematology 61st Annual Scientific Meeting.

RRMM is linked with a poor prognosis, necessitating the development of novel, effective therapies to improve survival outcomes. Belantamab mafodotin, a first-in-class monoclonal antibody that targets the B cell maturation antigen, showed, in the randomized, phase 2 DREAMM-2 study (ClinicalTrials.gov Identifier: NCT03525678), a median overall survival of 13.7 months among heavily pretreated patients with RRMM.

Single-agent use of belantamab mafodotin was, however, also associated with a significant ocular adverse event profile in DREAMM-2, with events ranging from blurred vision and dry eyes to keratopathy. For this post-hoc analysis, researchers evaluated ocular event outcomes among 95 patients treated for RRMM on DREAMM-2.

Continue Reading

The follow-up period was 13 months. Overall, 68 patients (72%) had a keratopathy event, with 60 patients having a ≥grade 2 event. The majority of these 60 patients (57%) recovered from their first keratopathy event during treatment, and a further 20% recovered at the end of treatment.

At last follow-up, 29 (48%) patients had recovered from ≥grade 2 keratopathy. Of the patients who had not recovered, 9 continued treatment, 5 discontinued treatment but continued follow-up, and 17 discontinued follow-up.

A total of 29 patients (48%) had more than 1 event, and 53 (56%) patients showed a decline in best corrected visual acuity. Among 17 patients whose best corrected visual acuity degraded to 20/50 or worse, 10 patients (59%) recovered during treatment.

“Long-term follow-up in this DREAMM-2 post-hoc analysis demonstrated that although ocular events were common, the majority of patients recovered while remaining on treatment,” the authors wrote. “No new ocular safety signals were observed at 13-month follow-up.”

Disclosure: Some [or one] study author(s) declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures. 


Lonial S, Nooka AK, Thulasi P, et al. Recovery of ocular events with longer-term follow-up in the DREAMM-2 study of single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma. Poster presented at: the British Society of Haematology 61st Annual Scientific Meeting; April 25-28, 2021; virtual.

This article originally appeared on Hematology Advisor